HHV8
MCID: KPS004
MIFTS: 76

Kaposi Sarcoma (HHV8)

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 57 12 73 20 58 36 54 42 15 70 32
Kaposi Sarcoma, Susceptibility to 57 29 13 6
Kaposi's Sarcoma 12 20 15 17
Angiofollicular Ganglionic Hyperplasia 58 70
Kaposi's Sarcoma of Soft Tissue 12 70
Kaposi's Sarcoma of Palate 12 70
Kaposi's Sarcoma of Lung 12 70
Multiple Idiopathic Pigmented Hemangiosarcoma, Susceptibility to 57
Multiple Idiopathic Pigmented Hemangiosarcoma 57
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
African Lymphadenopathic Kaposi's Sarcoma 12
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Sarcoma, Kaposi, Susceptibility to 39
Angiofollicular Lymph Hyperplasia 58
Lymphadenopathic Kaposi's Sarcoma 12
Multi-Centric Castleman's Disease 70
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 20
Non-Aids-Related Kaposi Sarcoma 70
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 20
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 20
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 70
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 20
Castleman Disease 58
Sarcoma, Kaposi 44
Hhv8 20
Kshv 20

Characteristics:

Orphanet epidemiological data:

58
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant


HPO:

31
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare circulatory system diseases
Developmental anomalies during embryogenesis
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8632
OMIM® 57 148000
KEGG 36 H00041
MeSH 44 D012514
MESH via Orphanet 45 C536362 D005871 D012514
UMLS via Orphanet 71 C0017531 C0036220 C2931179
UMLS 70 C0017531 C0036220 C0153560 more

Summaries for Kaposi Sarcoma

GARD : 20 Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions ( macules, nodules, plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). Kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-Saharan indigenous Africans), iatrogenic (associated with immunosuppressive drug therapy) and AIDS-associated (epidemic KS). Options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy ( immunotherapy ). The main aim is to restore immunity.

MalaCards based summary : Kaposi Sarcoma, also known as kaposi sarcoma, susceptibility to, is related to human herpesvirus 8 and sarcoma, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Kaposi sarcoma-associated herpesvirus infection and Viral carcinogenesis. The drugs Bleomycin and Efavirenz have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and lung, and related phenotypes are recurrent herpes and neoplasm of the skin

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in formation of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

OMIM® : 57 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000) (Updated 05-Apr-2021)

MedlinePlus : 42 Kaposi sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. They are made of cancer cells, blood vessels, and blood cells. KS is caused by infection with human herpesvirus-8 (HHV-8). Most people infected with HHV-8 don't get KS. It usually happens in People with weak immune systems, due to HIV/AIDS, drugs taken after an organ transplant, or another disease Older men of Jewish or Mediterranean descent Young men in Africa The skin lesions may not cause symptoms. But they can spread to other parts of the body, especially in people with HIV/AIDS. If they spread to the digestive tract or lungs, they can cause bleeding. Lesions on the lungs can also make it hard to breathe. Treatment depends on where the lesions are and how bad they are. Options include radiation therapy, surgery, chemotherapy, and biologic therapy. People with HIV/AIDS also take HIV/AIDS medicines. NIH: National Cancer Institute

KEGG : 36 Kaposi sarcoma (KS) is an angioproliferative disease classified into classic KS, endemic KS, iatrogenic KS, and HIV-associated KS (HIV-KS), however, share the same histological traits and are all associated with infection by the human herpesvirus 8 (HHV8; also known as KSHV). Evidence indicates that KS progression occurs upon the deregulated expression of anti-apoptotic genes (Bcl-2), oncogenes (c-myc, c-int, ras) and oncosuppressor genes (TP53), and is associated with the long-lasting expression of HHV8 latency genes (LANA, v-cyc D, v-FLIP, Kaposin). All these genes are, in fact, expressed or altered in most KS spindle cells in the nodular-late stage of KS. Bcl-2 acts as a major KS progression factor, and TP53 and c-myc may also have a role in disease progression. HHV8 latency gene products may be involved in KS progression due to their capability of promoting cell growth by direct effects or antiapoptotic effects.

Wikipedia : 73 Kaposi's sarcoma (KS) is a type of cancer that can form masses in the skin, lymph nodes, or other... more...

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1086)
# Related Disease Score Top Affiliating Genes
1 human herpesvirus 8 33.2 IL6ST IL6-AS1 IL6
2 sarcoma 32.2 VEGFA TP53 TNFRSF4 STAT3 PDGFB MYC
3 acquired immunodeficiency syndrome 32.1 TP53 MYC IL6 IFNA2
4 castleman disease 32.0 VEGFA IL6ST IL6
5 immune deficiency disease 31.6 IRF3 IL6 IFNB1 CXCL1 CCR8 AKT1
6 angiosarcoma 31.4 VEGFA TP53 MYC
7 lymphoma, non-hodgkin, familial 31.2 TP53 STAT3 MYC IL6 CDK6 AKT1
8 lymphangioma 31.2 VEGFA TP53 STAT3 MYC IFNA2
9 poems syndrome 31.2 VEGFA IL6 FGF2
10 monoclonal gammopathy of uncertain significance 31.1 TP53 MYC IL6
11 bronchiolitis obliterans 31.1 PDGFB IL6 CXCL8
12 intussusception 31.1 VEGFA IL6 FGF2
13 diffuse large b-cell lymphoma 31.0 VEGFA TP53 STAT3 MYC IL6 AKT1
14 neutropenia 31.0 TP53 IL6 IFNA2 CXCL8
15 thrombocytopenia 30.9 STIM1 STAT3 IL6 IFNB1 IFNA2 CXCL8
16 hemangioma 30.9 VEGFA TP53 PDGFB MYC IL6 IFNA2
17 burkitt lymphoma 30.9 TP53 STAT3 MYC IRF3 IL6
18 diarrhea 30.9 IL6 IFNB1 IFNA2 CXCL8
19 vascular cancer 30.9 VEGFA TP53 IFNA2 FGF2
20 skin disease 30.9 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
21 exanthem 30.8 VEGFA IL6 CXCL8 AKT1
22 vaccinia 30.8 TP53 IRF3 IL6 IFNB1
23 pericardial effusion 30.8 VEGFA IL6 FGF2
24 gastritis 30.8 TP53 IL6 CXCL8 CXCL1
25 myeloma, multiple 30.8 VEGFA TP53 STAT3 MYC IL6 FGF2
26 anogenital venereal wart 30.8 TP53 IFNB1 IFNA2
27 fibrosarcoma 30.8 TP53 PDGFB MYC FGF2
28 t-cell lymphoblastic leukemia/lymphoma 30.8 TNFRSF4 STAT3 MYC CDK6 AKT1
29 skin carcinoma 30.7 VEGFA TP53 STAT3 MYC IL6 IFNB1
30 pleural disease 30.7 VEGFA TP53 IL6 CXCL8
31 papilledema 30.7 VEGFA TP53 STAT3
32 varicose veins 30.7 VEGFA IL6 CXCL8
33 rheumatoid arthritis 30.6 VEGFA IL6ST IL6 IFNB1 CXCL8 CXCL1
34 osteosclerotic myeloma 30.6 VEGFA IL6
35 leukemia, chronic lymphocytic 30.6 VEGFA TP53 STAT3 MYC IL6 AKT1
36 hepatitis c 30.6 STAT3 IRF3 IFNB1 IFNA2
37 esophagitis 30.6 TP53 IL6 CXCL8
38 dysentery 30.6 IL6 IFNA2 CXCL8
39 mantle cell lymphoma 30.6 VEGFA TP53 STAT3 MYC IL6 CDK6
40 basal cell carcinoma 30.6 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
41 aplastic anemia 30.6 VEGFA TP53 STAT3 IL6 FGF2 CXCL8
42 combined immunodeficiency 30.6 VEGFA TNFRSF4 STIM1 STAT3 IL6 CXCL8
43 arteriovenous malformations of the brain 30.6 VEGFA IL6-AS1 IL6
44 retinal detachment 30.5 VEGFA PDGFB IL6 FGF2 CXCL8
45 human cytomegalovirus infection 30.5 IRF3 IL6 CXCL8
46 nervous system disease 30.5 VEGFA TP53 MYC IL6 IFNB1 FGF2
47 central nervous system lymphoma 30.5 TP53 MYC IL6
48 peripheral artery disease 30.5 VEGFA IL6 FGF2
49 nasopharyngeal carcinoma 30.5 VEGFA TP53 STAT3 MYC AKT1
50 allergic disease 30.5 TNFRSF4 STAT3 IL6 CXCL8

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Human phenotypes related to Kaposi Sarcoma:

58 31 (show top 50) (show all 54)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent herpes 58 31 obligate (100%) Obligate (100%) HP:0005353
2 neoplasm of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0008069
3 hypermelanotic macule 58 31 hallmark (90%) Very frequent (99-80%) HP:0001034
4 abnormality of the lower limb 58 31 hallmark (90%) Very frequent (99-80%) HP:0002814
5 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
6 hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0001028
7 abnormality of the spleen 58 31 frequent (33%) Frequent (79-30%) HP:0001743
8 abnormality of the gastrointestinal tract 58 31 frequent (33%) Frequent (79-30%),Occasional (29-5%) HP:0011024
9 papule 58 31 frequent (33%) Frequent (79-30%) HP:0200034
10 encephalopathy 58 31 frequent (33%) Frequent (79-30%) HP:0001298
11 skin nodule 58 31 frequent (33%) Frequent (79-30%) HP:0200036
12 generalized lymphadenopathy 58 31 frequent (33%) Frequent (79-30%),Occasional (29-5%) HP:0008940
13 abnormal retinal morphology 58 31 frequent (33%) Frequent (79-30%) HP:0000479
14 lymphoproliferative disorder 58 31 frequent (33%) Frequent (79-30%) HP:0005523
15 fatigue 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0012378
16 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
17 lymphedema 58 31 occasional (7.5%) Occasional (29-5%) HP:0001004
18 skin rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0000988
19 weight loss 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0001824
20 abnormal lung morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002088
21 venous insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0005293
22 abnormality of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0001392
23 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
24 skin plaque 58 31 occasional (7.5%) Occasional (29-5%) HP:0200035
25 nausea and vomiting 58 Occasional (29-5%)
26 renal insufficiency 58 Very rare (<4-1%)
27 anemia 58 Frequent (79-30%)
28 thrombocytopenia 58 Very rare (<4-1%)
29 jaundice 58 Occasional (29-5%)
30 hematuria 58 Very rare (<4-1%)
31 abdominal pain 58 Frequent (79-30%)
32 dyspnea 58 Very rare (<4-1%)
33 neoplasm 31 HP:0002664
34 cough 58 Occasional (29-5%)
35 macule 58 Very frequent (99-80%)
36 mediastinal lymphadenopathy 58 Frequent (79-30%)
37 intestinal obstruction 58 Very rare (<4-1%)
38 lymphadenopathy 58 Very frequent (99-80%)
39 elevated c-reactive protein level 58 Frequent (79-30%)
40 edema 31 HP:0000969
41 abdominal distention 58 Occasional (29-5%)
42 elevated erythrocyte sedimentation rate 58 Frequent (79-30%)
43 restrictive cardiomyopathy 58 Very rare (<4-1%)
44 follicular hyperplasia 58 Frequent (79-30%)
45 myelofibrosis 58 Very rare (<4-1%)
46 ureteral obstruction 58 Very rare (<4-1%)
47 decreased mean corpuscular volume 58 Occasional (29-5%)
48 anasarca 58 Very rare (<4-1%)
49 constitutional symptom 58 Frequent (79-30%)
50 neoplasm by anatomical site 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema

Clinical features from OMIM®:

148000 (Updated 05-Apr-2021)

UMLS symptoms related to Kaposi Sarcoma:


fever; pruritus; exanthema

MGI Mouse Phenotypes related to Kaposi Sarcoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 AKT1 CDK6 FGF2 IFNB1 IL6 IL6ST
2 immune system MP:0005387 10.34 AKT1 CCR8 CDK6 IFNB1 IL6 IL6ST
3 cardiovascular system MP:0005385 10.33 AKT1 CDK6 FGF2 IL6 IL6ST IRF3
4 cellular MP:0005384 10.31 AKT1 CDK6 FGF2 IL6 IL6ST IRF3
5 liver/biliary system MP:0005370 10.2 AKT1 CDK6 IL6 IL6ST MYC PDGFB
6 embryo MP:0005380 10.18 AKT1 CDK6 IL6ST MYC PDGFB STAT3
7 integument MP:0010771 10.18 AKT1 IL6 IL6ST MYC PDGFB STAT3
8 nervous system MP:0003631 10.18 AKT1 CCR8 CDK6 FGF2 IFNB1 IL6
9 neoplasm MP:0002006 10.1 AKT1 CDK6 FGF2 IFNB1 IL6 IL6ST
10 muscle MP:0005369 10.09 AKT1 CDK6 FGF2 IL6 MYC PDGFB
11 normal MP:0002873 9.97 AKT1 CCR8 IFNB1 IL6ST MYC STAT3
12 reproductive system MP:0005389 9.96 AKT1 CDK6 FGF2 IL6 IL6ST MYC
13 respiratory system MP:0005388 9.81 AKT1 IL6 IRF3 PDGFB STAT3 STIM1
14 skeleton MP:0005390 9.65 AKT1 FGF2 IFNB1 IL6 IL6ST MYC
15 vision/eye MP:0005391 9.32 CDK6 FGF2 IL6 IL6ST IRF3 PDGFB

Drugs & Therapeutics for Kaposi Sarcoma

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
2
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
3
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
4
Lopinavir Approved Phase 4 192725-17-0 92727
5
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
9
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
12
tannic acid Approved Phase 4 1401-55-4
13
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
14
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Immunosuppressive Agents Phase 4
20 Immunologic Factors Phase 4
21 Anti-Bacterial Agents Phase 4
22 Antifungal Agents Phase 4
23 Calcineurin Inhibitors Phase 4
24
Daunorubicin Approved Phase 3 20830-81-3 30323
25
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
26
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 441300 65140
27 Anti-Retroviral Agents Phase 3
28 Anti-HIV Agents Phase 3
29 Reverse Transcriptase Inhibitors Phase 3
30 Dideoxynucleosides Phase 2, Phase 3
31 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 3
32
Bexarotene Approved, Investigational Phase 2 153559-49-0 82146
33
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795 449171
34
Didanosine Approved Phase 2 69655-05-6 50599
35
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
36
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
37
Indinavir Approved Phase 2 150378-17-9 5362440
38
Vinblastine Approved Phase 2 865-21-4 241903 13342
39
Etravirine Approved Phase 2 269055-15-4 193962
40
Tipranavir Approved, Investigational Phase 2 174484-41-4 65027
41
Maraviroc Approved, Investigational Phase 2 376348-65-1 3002977
42
Nelfinavir Approved Phase 2 159989-64-7 64143
43
Nicotine Approved Phase 2 54-11-5 942 89594
44
Cidofovir Approved Phase 2 113852-37-2 60613
45
Saquinavir Approved, Investigational Phase 2 127779-20-8 60787
46
Siltuximab Approved, Investigational Phase 2 541502-14-1
47
Zidovudine Approved Phase 2 30516-87-1 35370
48
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
49
nivolumab Approved Phase 2 946414-94-4
50
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
2 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
3 Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled Trial Recruiting NCT04448873 Phase 4 Sirolimus
4 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
5 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
6 Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir Withdrawn NCT00361933 Phase 4 Valganciclovir
7 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
8 Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
9 A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma Completed NCT00002445 Phase 3 IM862
10 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
11 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
12 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
13 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
14 Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
15 A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
16 Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
17 A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067 Completed NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
18 Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma. Recruiting NCT04775173 Phase 3 Sirolimus
19 Valganciclovir for Suppression of HHV-8 Four Weeks Prior to Initiation of cART in Patients With Disseminated Kaposi Sarcoma Compare With Standard Therapy, Its Impact on the Development of IRIS and Attributable Mortality Unknown status NCT03296553 Phase 2 Valganciclovir;Antiretroviral Combinations
20 Treatment of HIV-Related Kaposi's Sarcoma and Stage I-III Slow-Proliferative Disease With Highly Active Antiretroviral Therapy (HAART) Unknown status NCT00003419 Phase 2
21 Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease Completed NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
22 A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma Completed NCT00002366 Phase 2 Ritonavir
23 Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging. Completed NCT02201420 Phase 2 Tc 99m tilmanocept
24 A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma Completed NCT00005931 Phase 2 SU5416
25 Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002212 Phase 2 Bexarotene
26 Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma. Completed NCT00002188 Phase 2 Alitretinoin
27 A Phase II Study of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV-Related Kaposi's Sarcoma Completed NCT00002314 Phase 2 Ro 24-7429
28 Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposi's Sarcoma Completed NCT00000996 Phase 2 Doxorubicin hydrochloride
29 A Randomized Phase II Trial to Determine the Safety, Tolerance, and Efficacy of Two Doses of Interferon Alfa-2b Combined With Didanosine in Patients With Kaposi's Sarcoma Completed NCT00001114 Phase 2 Interferon alfa-2b;Didanosine
30 Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00000687 Phase 2 Interferon alfa-2a;Zidovudine
31 Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Completed NCT00002167 Phase 2 Tin ethyl etiopurpurin
32 Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals Completed NCT00002189 Phase 2 Paclitaxel
33 A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Completed NCT00002131 Phase 2 Vesnarinone
34 Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed NCT00002259 Phase 2 Mitoxantrone hydrochloride
35 Comparison Study of Liposomal Doxorubicin With or Without Bleomycin and Vincristine for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma Completed NCT00001059 Phase 2 Doxorubicin hydrochloride (liposomal);Filgrastim;Bleomycin sulfate;Vincristine sulfate
36 Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy Completed NCT00000807 Phase 2 Etoposide
37 A Phase II Trial With the HIV Protease Inhibitor Indinavir for the Treatment of Classical Kaposi's Sarcoma Completed NCT00362310 Phase 2 indinavir
38 Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
39 Phase II Trial for the Treatment of Advanced Classical Kaposi's Sarcoma With the HIV Protease Inhibitor Indinavir in Combination With Chemotherapy Completed NCT01067690 Phase 2 Indinavir in association with Vinblastina +/- Bleomicina
40 Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma Completed NCT00055237 Phase 2
41 An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
42 Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) Completed NCT01276236 Phase 2 Maraviroc
43 Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial Completed NCT00295984 Phase 2 nicotine
44 A Phase I/II Study of Lenalidomide in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2 Lenalidomide
45 A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
46 A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat
47 A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA Completed NCT00019123 Phase 2 thalidomide
48 PHASE II PROTOCOL WITH LABORATORY CORRELATES OF 1-[(S)-3-HYDROXY-2-(PHOSPHOMETHOXY)PROPYL]CYTOSINE DIHYDRATE(CIDOFOVIR) IN PATIENTS WITH KAPOSI'S SARCOMA (KS) Completed NCT00019240 Phase 2 cidofovir
49 A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma Completed NCT00005042 Phase 2 semaxanib
50 A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


alitretinoin
doxorubicin hydrochloride liposome
Etoposide
etoposide phosphate
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Paclitaxel
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
siltuximab
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Genetic tests related to Kaposi Sarcoma:

# Genetic test Affiliating Genes
1 Kaposi Sarcoma, Susceptibility to 29 IL6

Anatomical Context for Kaposi Sarcoma

MalaCards organs/tissues related to Kaposi Sarcoma:

40
Skin, Endothelial, Lung, Kidney, Liver, Bone, Lymph Node

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 13381)
# Title Authors PMID Year
1
An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. 54 61 6 57
11001912 2000
2
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. 61 57
22490805 2012
3
Salivary lactoferrin is recognized by the human herpesvirus-8. 61 57
15955101 2005
4
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. 57 61
15220918 2004
5
Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. 61 57
15220917 2004
6
Epidemiology of classic Kaposi's sarcoma in the Israeli Jewish population between 1960 and 1998. 61 57
14583765 2003
7
Kaposi's sarcoma-associated herpesvirus--the high cost of viral survival. 61 57
13679522 2003
8
Expression of human herpesvirus 8 in primary pulmonary hypertension. 57 61
13679525 2003
9
Structure of an extracellular gp130 cytokine receptor signaling complex. 61 57
11251120 2001
10
High incidence of classical Kaposi's sarcoma in Iceland and the Faroe Islands. 61 57
9569061 1998
11
Monoclonal origin of multicentric Kaposi's sarcoma lesions. 57 61
9077377 1997
12
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. 61 57
8705864 1996
13
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. 61 57
8705863 1996
14
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. 57 61
7997879 1994
15
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. 61 57
6975437 1981
16
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. 61 57
6272109 1981
17
Opportunistic infections and Kaposi's sarcoma in homosexual men. 57 61
6272112 1981
18
Kaposi's sarcoma. Retrospective study of 90 cases with particular emphasis on the familial occurrence, ethnic background and prevalence of other diseases. 61 57
7304649 1981
19
Familial Kaposi's sarcoma. 61 57
435392 1979
20
Kaposi's sarcoma in a father and son. 61 57
13788156 1960
21
Epidemiology and Genetic Variability of HHV-8/KSHV among Rural Populations and Kaposi's Sarcoma Patients in Gabon, Central Africa. Review of the Geographical Distribution of HHV-8 K1 Genotypes in Africa. 42 61
33503816 2021
22
Analysis of KSHV B lymphocyte lineage tropism in human tonsil reveals efficient infection of CD138+ plasma cells. 61 42
33075105 2020
23
ETIOPATHOGENIC, EPIDEMIOLOGIC AND CLINICAL-THERAPEUTIC COMPARISON OF NON-HODGKIN'S LYMPHOMA AND KAPOSI'S SARCOMA. 42 61
33237165 2020
24
Cloning a human saliva-derived peptide for preventing KSHV transmission. 57
22377758 2012
25
Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. 6
17623760 2007
26
Interleukin-6 involvement in brain arteriovenous malformations. 6
16278864 2006
27
Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. 6
16150725 2005
28
Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. 6
15472205 2004
29
Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. 6
15331795 2004
30
Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. 6
15070960 2004
31
Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. 6
12719374 2003
32
Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. 6
12519862 2003
33
The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. 6
12560873 2003
34
The -597 G-->A and -174 G-->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. 6
11889177 2002
35
Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. 6
10720087 2000
36
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. 6
9769329 1998
37
Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation. 61 54
19690161 2009
38
Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. 54 61
19654515 2009
39
Linear IgA bullous dermatosis induced by interferon-alpha 2a. 54 61
19508467 2009
40
Kaposi's sarcoma-associated herpesvirus-G protein-coupled receptor-expressing endothelial cells exhibit reduced migration and stimulated chemotaxis by chemokine inverse agonists. 61 54
19258523 2009
41
ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin. 61 54
19260835 2009
42
The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. 54 61
18836096 2009
43
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. 54 61
18566614 2008
44
The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. 61 54
18758494 2008
45
Sirolimus (rapamycin): from the soil of Easter Island to a bright future. 54 61
17583372 2007
46
Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells. 54 61
17868650 2007
47
AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa? 54 61
17656146 2007
48
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients. 54 61
17721110 2007
49
Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate. 61 54
16572284 2007
50
Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". 61 54
17386117 2007

Variations for Kaposi Sarcoma

ClinVar genetic disease variations for Kaposi Sarcoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IL6-AS1 , IL6 NG_011640.1:g.4880C>G SNV risk factor 14718 GRCh37: 7:22766645-22766645
GRCh38: 7:22727026-22727026

Cosmic variations for Kaposi Sarcoma:

9 (show top 50) (show all 60)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93992510 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 6
2 COSM98338978 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 6
3 COSM98373331 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 6
4 COSM93554172 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 6
5 COSM93451505 RAC1 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 6
6 COSM92729038 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 6
7 COSM117948203 PTPRD soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 6
8 COSM132326062 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 6
9 COSM91028178 PTPRD soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 6
10 COSM101931022 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 6
11 COSM132607215 PTPRD soft tissue,lung,sarcoma,NS c.2912C>T p.A971V 9:8404587-8404587 6
12 COSM102156539 PTPRD soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 6
13 COSM102254463 PTPRD soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 6
14 COSM92957889 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 6
15 COSM102059370 PTPRD soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 6
16 COSM106841030 PTCH1 soft tissue,lung,sarcoma,NS c.2468T>G p.F823C 9:95458260-95458260 6
17 COSM103461667 PTCH1 soft tissue,lung,sarcoma,NS c.2468T>G p.F823C 9:95458260-95458260 6
18 COSM110727009 PTCH1 soft tissue,lung,sarcoma,NS c.2723T>G p.F908C 9:95458260-95458260 6
19 COSM90842465 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 6
20 COSM108525670 PTCH1 soft tissue,lung,sarcoma,NS c.2723T>G p.F908C 9:95458260-95458260 6
21 COSM108470656 PTCH1 soft tissue,lung,sarcoma,NS c.2468T>G p.F823C 9:95458260-95458260 6
22 COSM98545043 PTCH1 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 6
23 COSM87210160 PIK3CA soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 6
24 COSM149000769 PIK3CA soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 6
25 COSM91788538 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 6
26 COSM102558626 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 6
27 COSM101270110 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 6
28 COSM93619977 PBRM1 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 6
29 COSM88073526 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 6
30 COSM102926575 PBRM1 soft tissue,lung,sarcoma,NS c.2879G>A p.R960H 3:52589201-52589201 6
31 COSM104534913 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 6
32 COSM102955053 PBRM1 soft tissue,lung,sarcoma,NS c.2879G>A p.R960H 3:52589201-52589201 6
33 COSM98770048 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 6
34 COSM98743623 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 6
35 COSM91962426 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 6
36 COSM97107943 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 6
37 COSM134990158 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 6
38 COSM87804075 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 6
39 COSM134990190 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 6
40 COSM91859752 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 6
41 COSM134615012 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 6
42 COSM134614978 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 6
43 COSM87804055 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 6
44 COSM91859771 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 6
45 COSM113328424 HGF soft tissue,lung,sarcoma,NS c.1696G>T p.V566L 7:81706333-81706333 6
46 COSM87850803 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 6
47 COSM151007219 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 6
48 COSM99664612 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 6
49 COSM100583919 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 6
50 COSM118450453 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 6

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to KEGG:

36
# Name Kegg Source Accession
1 Kaposi sarcoma-associated herpesvirus infection hsa05167
2 Viral carcinogenesis hsa05203

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 VEGFA TP53 TNFRSF4 STIM1 STAT3 PDGFB
2
Show member pathways
13.85 VEGFA TP53 TNFRSF4 STAT3 PDGFB MYC
3
Show member pathways
13.74 TP53 TNFRSF4 STAT3 MYC IL6ST IL6
4
Show member pathways
13.62 VEGFA TP53 STAT3 PDGFB MYC IL6
5
Show member pathways
13.5 TP53 TNFRSF4 STAT3 PDGFB IL6 FGF2
6
Show member pathways
13.4 VEGFA TP53 STIM1 PDGFB IRF3 IFNB1
7
Show member pathways
13.39 TNFRSF4 PDGFB IL6 FGF2 CXCL8 CXCL1
8
Show member pathways
13.23 TP53 STAT3 MYC IRF3 IL6 IFNB1
9
Show member pathways
13.22 VEGFA TP53 STAT3 IL6 IFNB1 CXCL8
10
Show member pathways
12.98 VEGFA TP53 STAT3 PDGFB MYC CDK6
11
Show member pathways
12.98 VEGFA TP53 PDGFB MYC IRF3 IL6
12
Show member pathways
12.94 VEGFA TP53 TNFRSF4 STAT3 PDGFB MYC
13 12.9 TP53 IRF3 IL6 IFNB1 IFNA2 AKT1
14 12.86 VEGFA TP53 PDGFB MYC FGF2 AKT1
15
Show member pathways
12.84 TP53 STAT3 MYC IRF3 IL6 IFNB1
16
Show member pathways
12.83 TP53 MYC FGF2 CDK6 AKT1
17
Show member pathways
12.8 TP53 STIM1 PDGFB FGF2 AKT1
18
Show member pathways
12.79 IRF3 IL6 IFNB1 IFNA2 CXCL8
19
Show member pathways
12.78 TP53 STAT3 PDGFB FGF2 CDK6 AKT1
20
Show member pathways
12.68 VEGFA TP53 STAT3 PDGFB MYC IL6
21 12.66 VEGFA TP53 STAT3 PDGFB MYC IL6ST
22 12.65 VEGFA TP53 STAT3 PDGFB MYC CDK6
23
Show member pathways
12.65 TP53 STAT3 PDGFB MYC IL6 FGF2
24
Show member pathways
12.62 VEGFA TP53 STAT3 MYC FGF2 AKT1
25 12.5 TP53 IRF3 IFNB1 CXCL8 AKT1
26
Show member pathways
12.48 STAT3 PDGFB MYC IL6ST IL6 IFNB1
27
Show member pathways
12.46 TP53 STAT3 MYC AKT1
28 12.46 VEGFA STIM1 PDGFB FGF2
29
Show member pathways
12.44 IL6ST IL6 CXCL8 CXCL1 CCR8
30
Show member pathways
12.44 STAT3 IL6ST IL6 CXCL8 CXCL1 AKT1
31
Show member pathways
12.43 TP53 IRF3 IL6 FGF2 CXCL8 AKT1
32
Show member pathways
12.42 TP53 STAT3 IL6ST IL6 AKT1
33 12.41 TP53 MYC IL6 AKT1
34
Show member pathways
12.41 VEGFA TP53 STAT3 IL6ST AKT1
35 12.41 VEGFA TP53 STAT3 MYC FGF2 AKT1
36 12.4 TP53 STAT3 IRF3 IL6ST CDK6 CCR8
37 12.34 TP53 MYC IL6 CXCL8
38
Show member pathways
12.34 IRF3 IL6 IFNB1 CXCL8
39 12.33 IRF3 IL6 IFNB1 IFNA2 CXCL8 CXCL1
40
Show member pathways
12.33 VEGFA TP53 STAT3 PDGFB MYC IRF3
41 12.31 IL6 IFNB1 IFNA2 AKT1
42 12.28 VEGFA TP53 STAT3 MYC IL6 AKT1
43
Show member pathways
12.28 TP53 PDGFB MYC IRF3 IL6 IFNB1
44
Show member pathways
12.25 STAT3 IL6ST FGF2 AKT1
45 12.25 TP53 MYC IL6 CXCL8 CDK6 AKT1
46 12.24 TP53 IRF3 IFNB1 IFNA2
47 12.23 VEGFA TP53 MYC AKT1
48 12.23 STAT3 MYC IL6ST FGF2 AKT1
49
Show member pathways
12.22 STAT3 PDGFB MYC AKT1
50 12.2 IRF3 IL6 IFNB1 CXCL8 AKT1

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 VEGFA PDGFB IL6ST IL6 IFNB1 IFNA2
2 extracellular space GO:0005615 9.32 VEGFA PDGFB IL6ST IL6 IFNB1 IFNA2
3 interleukin-6 receptor complex GO:0005896 8.96 IL6ST IL6

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 VEGFA STAT3 PDGFB IL6ST IL6 FGF2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 VEGFA TP53 STAT3 MYC IRF3 IL6
3 immune response GO:0006955 10.1 TNFRSF4 IL6 CXCL8 CXCL1 CCR8
4 negative regulation of apoptotic process GO:0043066 10.08 VEGFA TP53 MYC IL6ST IL6 AKT1
5 negative regulation of cell proliferation GO:0008285 10.06 TP53 STAT3 IL6 CXCL8 CXCL1 CDK6
6 positive regulation of cell proliferation GO:0008284 10.01 VEGFA STAT3 PDGFB MYC IL6ST IL6
7 defense response to virus GO:0051607 9.99 IRF3 IL6 IFNB1 IFNA2
8 inflammatory response GO:0006954 9.98 TNFRSF4 STAT3 IL6 IFNA2 CXCL8 CXCL1
9 cellular response to lipopolysaccharide GO:0071222 9.96 IRF3 IL6 CXCL8 CXCL1
10 chemotaxis GO:0006935 9.94 FGF2 CXCL8 CXCL1 CCR8
11 defense response GO:0006952 9.93 STAT3 IFNB1 IFNA2 CXCL8 CXCL1
12 cell cycle arrest GO:0007050 9.92 TP53 MYC CXCL8 CDK6
13 cellular response to hypoxia GO:0071456 9.92 VEGFA TP53 MYC AKT1
14 positive regulation of angiogenesis GO:0045766 9.92 VEGFA STIM1 STAT3 FGF2 CXCL8
15 negative regulation of gene expression GO:0010629 9.91 VEGFA TP53 PDGFB IFNA2 FGF2 CXCL8
16 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP53 STAT3 PDGFB MYC IRF3 IL6
17 positive regulation of MAPK cascade GO:0043410 9.89 VEGFA PDGFB IL6 FGF2
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 VEGFA TP53 PDGFB IL6
19 chemokine-mediated signaling pathway GO:0070098 9.87 CXCL8 CXCL1 CCR8
20 type I interferon signaling pathway GO:0060337 9.87 IRF3 IFNB1 IFNA2
21 positive regulation of endothelial cell migration GO:0010595 9.87 VEGFA FGF2 AKT1
22 positive regulation of epithelial cell proliferation GO:0050679 9.86 VEGFA MYC FGF2
23 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 PDGFB IL6